Abstract
Aim: A novel, Investigational Wearable Infusor (IWI) was evaluated in a randomized, controlled, crossover, open-label study to determine if its delivery of subcutaneous immunoglobulin (IgPro20) ach... Plain language summary Patients with primary immunodeficiency (PID) are at a higher risk of developing serious infections than healthy individuals. Immunoglobulin G (IgG) replacement therapy reduce...
Funding Information
  • CSL Behring
  • National Institutes of Health (AI-061093, AI-086037, AI-48693)

This publication has 22 references indexed in Scilit: